National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, University of Lyon, Institut National de Recherche pour l'Agriculture et l'Environnement (INRAE), European Reference Network (ERN-LUNG), Lyon, France.
Department of Experimental and Clinical Medicine, Careggi University Hospital, Florence, Italy.
Am J Respir Crit Care Med. 2022 Aug 1;206(3):247-259. doi: 10.1164/rccm.202111-2607PP.
When considering the diagnosis of idiopathic pulmonary fibrosis (IPF), experienced clinicians integrate clinical features that help to differentiate IPF from other fibrosing interstitial lung diseases, thus generating a "pre-test" probability of IPF. The aim of this international working group perspective was to summarize these features using a tabulated approach similar to chest HRCT and histopathologic patterns reported in the international guidelines for the diagnosis of IPF, and to help formally incorporate these clinical likelihoods into diagnostic reasoning to facilitate the diagnosis of IPF. The committee group identified factors that influence the clinical likelihood of a diagnosis of IPF, which was categorized as a pre-test clinical probability of IPF into "high" (70-100%), "intermediate" (30-70%), or "low" (0-30%). After integration of radiological and histopathological features, the post-test probability of diagnosis was categorized into "definite" (90-100%), "high confidence" (70-89%), "low confidence" (51-69%), or "low" (0-50%) probability of IPF. A conceptual Bayesian framework was created, integrating the clinical likelihood of IPF ("pre-test probability of IPF") with the HRCT pattern, the histopathology pattern when available, and/or the pattern of observed disease behavior, into a "post-test probability of IPF." The diagnostic probability of IPF was expressed using an adapted diagnostic ontology for fibrotic interstitial lung diseases. The present approach will help incorporate the clinical judgment into the diagnosis of IPF, thus facilitating the application of IPF diagnostic guidelines and, ultimately improving diagnostic confidence and reducing the need for invasive diagnostic techniques.
在考虑特发性肺纤维化 (IPF) 的诊断时,经验丰富的临床医生会综合考虑有助于将 IPF 与其他纤维性间质性肺疾病区分开来的临床特征,从而产生 IPF 的“初步测试”概率。本国际工作组的目的是使用类似于胸部高分辨率 CT(HRCT)和国际 IPF 诊断指南中报告的组织病理学模式的表格方法总结这些特征,并帮助正式将这些临床可能性纳入诊断推理,以促进 IPF 的诊断。委员会小组确定了影响 IPF 诊断临床可能性的因素,将 IPF 的初步测试临床概率分为“高”(70-100%)、“中”(30-70%)或“低”(0-30%)。整合影像学和组织病理学特征后,诊断后概率分为“明确”(90-100%)、“高度置信”(70-89%)、“低度置信”(51-69%)或“低度”(0-50%)。创建了一个概念性贝叶斯框架,将 IPF 的临床可能性(“IPF 的初步测试概率”)与 HRCT 模式、有条件时的组织病理学模式以及/或观察到的疾病行为模式整合到“IPF 的后测试概率”中。使用纤维化间质性肺疾病的改编诊断本体论来表达 IPF 的诊断概率。该方法有助于将临床判断纳入 IPF 的诊断,从而促进 IPF 诊断指南的应用,最终提高诊断信心并减少对有创诊断技术的需求。